Pereyre S, Métifiot M, Cazanave C, Renaudin H, Charron A, Bébéar C, Bébéar C M
Laboratoire de Bactériologie EA 3671, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France.
Int J Antimicrob Agents. 2007 Feb;29(2):207-11. doi: 10.1016/j.ijantimicag.2006.09.008. Epub 2006 Dec 28.
Resistant mutants of Ureaplasma parvum were selected by serial passages of a susceptible strain in subinhibitory concentrations of different macrolides and related antibiotics (erythromycin, azithromycin, josamycin, quinupristin, quinupristin/dalfopristin, pristinamycin and telithromycin). Mechanisms of resistance were characterised by sequencing portions of genes encoding 23S rRNA and ribosomal proteins L4 and L22. Mutants with significantly increased minimum inhibitory concentrations could be selected with all the selector antibiotics, except quinupristin and pristinamycin. Mutants harboured mutations in domain V of the 23S rRNA gene at nucleotides G2056, G2057 or A2058 (Escherichia coli numbering) and in conserved portions of ribosomal proteins L4 and L22. Most of the mutations were associated with complete loss of macrolide and ketolide activity, whereas streptogramin combinations were less affected.
通过将敏感菌株在不同大环内酯类及相关抗生素（红霉素、阿奇霉素、交沙霉素、奎奴普丁、奎奴普丁/达福普汀、普那霉素和泰利霉素）的亚抑菌浓度下连续传代，筛选出微小脲原体的耐药突变株。通过对编码23S rRNA及核糖体蛋白L4和L22的基因部分进行测序，对耐药机制进行了表征。除奎奴普丁和普那霉素外，所有筛选抗生素均可筛选出最低抑菌浓度显著升高的突变株。突变株在23S rRNA基因的V结构域中核苷酸G2056、G2057或A2058（大肠杆菌编号）以及核糖体蛋白L4和L22的保守部分存在突变。大多数突变与大环内酯类和酮内酯类活性的完全丧失有关，而链阳霉素组合受影响较小。
